ExchangeDEX+
Buy CryptoMarketsSpotFuturesGOLDEarnEvent Center
More
Alex Tzoukas joins Epikast’s Board of Directors Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos NEW YORK and ATHENS, Greece, Jan. 30, 2026Alex Tzoukas joins Epikast’s Board of Directors Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos NEW YORK and ATHENS, Greece, Jan. 30, 2026

Kos Biotechnology Partners Announces Inaugural Investment, Leads Epikast’s Financing Round

Author: AI JournalSource: AI Journal
2026/01/31 02:30
  • Alex Tzoukas joins Epikast’s Board of Directors
  • Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos

NEW YORK and ATHENS, Greece, Jan. 30, 2026 /PRNewswire/ — Kos Biotechnology Partners (“Kos”), a global life sciences investment firm, today announced the closing of a financing round in Epikast, a premier provider of technology-enabled commercial and clinical services for the biopharmaceutical industry. This transaction marks the first investment from Kos’ inaugural fund, which is focused on a broad range of investment stages, including the seeding and scaling of high-impact life sciences platforms.

Kos led the round with significant participation from a syndicate of new and existing investors. In conjunction with the financing, Alex Tzoukas, Managing Partner and Co-Founder at Kos, will join Epikast’s Board of Directors.

The capital infusion will enhance Epikast’s proprietary technology platform and the scaling of its specialized service teams. Epikast bridges the gap between high-level medical expertise and cost-efficient operations by leveraging its Greece-based operational hub to serve global biopharmaceutical clients.

Alex Tzoukas, Managing Partner and Co-Founder of Kos Biotechnology Partners commented: “Epikast represents an exciting investment for our new fund. The company has developed a differentiated, tech-enabled pharma services model that addresses a clear inefficiency in how biopharma companies engage with healthcare providers and patients. We are pleased to lead this round and support the company as it scales.”

Dr. Stelios Papadopoulos, Chairman of Epikast, added: “We are pleased to welcome Kos Biotechnology Partners as lead investor in this round. Kos brings deep sector expertise and a strong connection to both the US and Greek innovation ecosystems, which aligns well with Epikast’s operating model. Alex’s addition to the board adds valuable perspective as we enter the next phase of growth.”

Dr. Simos Simeonidis, Managing Partner and Co-Founder of Kos Biotechnology Partners commented: “We are pleased to partner with Stelios and his team at Epikast with the first investment from our fund. Alex’s deep background as a life sciences investor, investment banker, and operator will further enhance the strong expertise already present on Epikast’s Board.”

Dr. Vangelis Vergetis, CEO of Epikast, concluded: “This financing reinforces Epikast’s strong momentum. We place a premium on partnering with individuals who bring deep expertise and strong judgment. Alex Tzoukas, Simos Simeonidis, and Nikos Kostaras exemplify that and will be valuable partners as we advance our next phase.”

About Epikast

Epikast is a technology-enabled biopharmaceutical services company headquartered in New York with core operations in Athens, Greece. The company provides a comprehensive suite of remote commercial, medical, market access, and patient support services. By combining highly trained medical professionals with a proprietary technology stack, Epikast delivers high-quality engagement and data-driven insights to biopharma clients at a significantly optimized cost structure. It currently partners with several global top 10 pharma companies and smaller biotechnology companies as they commercialize their products in the US and Europe.

About Kos Biotechnology Partners

Kos Biotechnology Partners is a global investment firm founded in 2025 by Dr. Simos Simeonidis and Alex Tzoukas, with a focus on identifying, supporting, and scaling innovative, high-potential opportunities in the life sciences sector. With the launch of its inaugural fund, Kos partners with experienced management teams to build enduring products, services, and platforms through strategic capital, deep operational expertise, and a long-term perspective on value creation.

Media Contacts: info@kosbp.com, info@epikast.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kos-biotechnology-partners-announces-inaugural-investment-leads-epikasts-financing-round-302675286.html

SOURCE Kos Biotechnology Partners

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

The Channel Factories We’ve Been Waiting For

The Channel Factories We’ve Been Waiting For

The post The Channel Factories We’ve Been Waiting For appeared on BitcoinEthereumNews.com. Visions of future technology are often prescient about the broad strokes while flubbing the details. The tablets in “2001: A Space Odyssey” do indeed look like iPads, but you never see the astronauts paying for subscriptions or wasting hours on Candy Crush.  Channel factories are one vision that arose early in the history of the Lightning Network to address some challenges that Lightning has faced from the beginning. Despite having grown to become Bitcoin’s most successful layer-2 scaling solution, with instant and low-fee payments, Lightning’s scale is limited by its reliance on payment channels. Although Lightning shifts most transactions off-chain, each payment channel still requires an on-chain transaction to open and (usually) another to close. As adoption grows, pressure on the blockchain grows with it. The need for a more scalable approach to managing channels is clear. Channel factories were supposed to meet this need, but where are they? In 2025, subnetworks are emerging that revive the impetus of channel factories with some new details that vastly increase their potential. They are natively interoperable with Lightning and achieve greater scale by allowing a group of participants to open a shared multisig UTXO and create multiple bilateral channels, which reduces the number of on-chain transactions and improves capital efficiency. Achieving greater scale by reducing complexity, Ark and Spark perform the same function as traditional channel factories with new designs and additional capabilities based on shared UTXOs.  Channel Factories 101 Channel factories have been around since the inception of Lightning. A factory is a multiparty contract where multiple users (not just two, as in a Dryja-Poon channel) cooperatively lock funds in a single multisig UTXO. They can open, close and update channels off-chain without updating the blockchain for each operation. Only when participants leave or the factory dissolves is an on-chain transaction…
Share
BitcoinEthereumNews2025/09/18 00:09
Shanghai residents flock to sell gold as its price hit record highs

Shanghai residents flock to sell gold as its price hit record highs

The post Shanghai residents flock to sell gold as its price hit record highs appeared on BitcoinEthereumNews.com. Gold surged over the $5,500-per-ounce milestone
Share
BitcoinEthereumNews2026/01/31 01:48
Polygon Tops RWA Rankings With $1.1B in Tokenized Assets

Polygon Tops RWA Rankings With $1.1B in Tokenized Assets

The post Polygon Tops RWA Rankings With $1.1B in Tokenized Assets appeared on BitcoinEthereumNews.com. Key Notes A new report from Dune and RWA.xyz highlights Polygon’s role in the growing RWA sector. Polygon PoS currently holds $1.13 billion in RWA Total Value Locked (TVL) across 269 assets. The network holds a 62% market share of tokenized global bonds, driven by European money market funds. The Polygon POL $0.25 24h volatility: 1.4% Market cap: $2.64 B Vol. 24h: $106.17 M network is securing a significant position in the rapidly growing tokenization space, now holding over $1.13 billion in total value locked (TVL) from Real World Assets (RWAs). This development comes as the network continues to evolve, recently deploying its major “Rio” upgrade on the Amoy testnet to enhance future scaling capabilities. This information comes from a new joint report on the state of the RWA market published on Sept. 17 by blockchain analytics firm Dune and data platform RWA.xyz. The focus on RWAs is intensifying across the industry, coinciding with events like the ongoing Real-World Asset Summit in New York. Sandeep Nailwal, CEO of the Polygon Foundation, highlighted the findings via a post on X, noting that the TVL is spread across 269 assets and 2,900 holders on the Polygon PoS chain. The Dune and https://t.co/W6WSFlHoQF report on RWA is out and it shows that RWA is happening on Polygon. Here are a few highlights: – Leading in Global Bonds: Polygon holds 62% share of tokenized global bonds (driven by Spiko’s euro MMF and Cashlink euro issues) – Spiko U.S.… — Sandeep | CEO, Polygon Foundation (※,※) (@sandeepnailwal) September 17, 2025 Key Trends From the 2025 RWA Report The joint publication, titled “RWA REPORT 2025,” offers a comprehensive look into the tokenized asset landscape, which it states has grown 224% since the start of 2024. The report identifies several key trends driving this expansion. According to…
Share
BitcoinEthereumNews2025/09/18 00:40